You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
大行評級|建銀國際:上調中國生物製藥目標價至4.4港 前景持續改善
格隆匯 08-14 15:49

建銀國際發表報吿指出,中國生物製藥中期收入按年增長11.1%至159億元,高過該行預期的148億元。抗腫瘤藥物業務增長強勁,按年增長19.5%至54億元,超過該行預期的49億元。毛利率達82.1%,符合預期。儘管銷售開支高於預期,但被較低的行政及研發費用所抵銷,經營利用率按季升0.3個百分點至24.3%,符合預期。

該行將中生製藥今年收入預測上調14.8%,主要由於核心創新藥物的抗腫瘤藥物銷售增長加快。另將今年銷售費用預測上調18.7%,對公司目標價由4.1港元上調至4.4港元,認為其前景持續改善,維持“跑贏大市”評級。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account